PresentationAmy Bachrodt Good morning, everyone, and thank you for joining us today for Maze's event on data from the Phase I clinical trial of MZE782, an oral SLC6A19 inhibitor with potential to treat phenylketonuria or PKU in chronic kidney disease or CKD. [Operator Instructions]. As a reminder, this conference call is being recorded. Before we start, I would like to remind you that today's event, which is intended for the investment community, will include forward-looking statements based on current expe ...

慢性肾病诊断技术突破 - 研究团队开发了基于视网膜图像的肾脏智能诊断系统（KIDS），实现了慢性肾病（CKD）的无创筛查和病理类型识别 [2][3] - KIDS在多中心验证中表现出色，慢性肾病筛查AUC达0.839-0.993，病理类型识别AUC为0.790-0.932 [3][11][12] - 系统诊断准确率比肾病专家高26.98%，并能预测5年疾病进展 [12][16] 慢性肾病临床挑战 - 全球约8.5亿人受CKD影响，终末期可能危及生命 [6] - 传统肾脏活检存在局限性：11%病例出现血肿，1.6%需输血，且欠发达地区技术资源匮乏 [6] - 缺乏活检时治疗方案依赖专家主观判断，预后难以确定 [6] 技术创新价值 - KIDS通过视网膜图像结合临床数据实现病理预测，突破现有AI辅助诊断局限 [7][11] - 系统在中国南方、喀什和索马里等多民族数据集验证通用性 [11] - 无创特性特别适合高风险患者和资源匮乏地区，有望降低终末期肾病发病率 [16]